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Background: Transcutaneous electrical nerve stimulation (TENS) is a non-pharmacologic treatment for pain relief. In
previous animal studies, TENS effectively alleviated Complete Freund’s Adjuvant (CFA)- or carrageenan-induced
inflammatory pain. Although TENS is known to produce analgesia via opioid activation in the brain and at the
spinal level, few reports have investigated the signal transduction pathways mediated by TENS. Prior studies have
verified the importance of the activation of extracellular signal-regulated kinase (ERK) signal transduction pathway in
the spinal cord dorsal horn (SCDH) in acute and persistent inflammatory pains. Here, by using CFA rat model, we
tested the efficacy of TENS on inhibiting the expressions of p-ERK1/2 and of its downstream cyclooxygenase-2
(COX-2) and the level of prostaglandin E2 (PGE2) at spinal level.
Methods: Rats were randomly divided into control, model and TENS groups, and injected subcutaneously with
100 μl CFA or saline in the plantar surface of right hind paw. Rats in the TENS group were treated with TENS
(constant aquare wave, 2 Hz and 100 Hz alternating frequencies, intensities ranging from 1 to 2 mA, lasting for
30 min each time) at 5 h and 24 h after injection. Paw withdrawal thresholds (PWTs) were measured with dynamic
plantar aesthesiometer at 3d before modeling and 5 h, 6 h, and 25 h after CFA injection. The ipsilateral sides of the
lumbar spinal cord dosral horns were harvested for detecting the expressions of p-ERK1/2 and COX-2 by western
blot analysis and qPCR, and PGE2 by ELISA.
Results: CFA-induced periphery inflammation decreased PWTs and increased paw volume of rats. TENS treatment
significantly alleviated mechanical hyperalgesia caused by CFA. However, no anti-inflammatory effect of TENS was
observed. Expression of p-ERK1/2 protein and COX-2 mRNA was significantly up-regualted at 5 h and 6 h after CFA
injection, while COX-2 and PGE2 protein level only increased at 6 h after modeling. Furthermore, the high
expression of p-ERK1/2 and COX-2, and over-production of PGE2 induced by CFA, were suppressed by TENS
administration.
Conclusions: TENS may be an effective therapy in controlling inflammatory pain induced by CFA. Its analgesic
effect may be associated with the inhibition of activation of the spinal ERK1/2-COX-2 pathway.
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Inflammatory pain decreases the quality of life of patients
and is thus a major health care problem. Inflammation-
induced pain is a complex pathological process occurring
in both central nervous system (CNS) and peripheral ner-
vous system. Recent studies have revealed that, the mito-
gen activated protein kinases (MAPKs) family, located in
the spinal cord, plays pivotal roles in regulating inflamma-
tory pain [1].
Extracellular signal-regulated kinase (ERK), the first
member identified from the MAPK family, was initially
known as a primary effecter of growth factor receptor
signaling. However, increasing evidences have also pin-
pointed ERK as an important mediator in adult neuronal
plasticity [2]. Ji et al. (1999) have shown that phosphor-
ylation (activation) of ERK in the spinal cord dorsal horn
(SCDH) is depended upon nociceptive activity [3]. Stud-
ies addressing the role of ERK1/2 in inflammatory pain
have demonstrated that ERK1/2 activation is induced in
SCDH by: hind paw inflammation with formalin [4],
Complete Freund’s Adjuvant (CFA) [5,6], scorpion BmK
venom [7], by chronic bladder inflammation [8], and
by monoarthritis in the ankle [9], all contributes to
inflammation-induced hyperalgesia and allodynia. Fur-
ther studies have also revealed that intrathecal injection
of specific MEK (ERK1/2’s upstream MAPK kinase) in-
hibitor, significantly reduces the heat and mechanical
hypersensitivity induced by peripheral inflammation
[4-9]. Overall, these findings indicate that ERK1/2 acti-
vation, followed by COX-2 [10], plays an important role
in the generation of inflammatory pain, and thus would
be a suitable therapeutic target for inflammatory pain
treatment. This hypothesis is strengthened by the fact
that COX-2 was believed to contribute to inflammatory
pain for a long time.
Transcutaneous electrical nerve stimulation (TENS) is
an effective pain treatment method significantly attenu-
ating multiple types of pain, such as inflammatory and
neuropathic pains. Previous clinical studies have shown
a positive effect of TENS analgesia in patients with
osteoarthritis pain, low back pain and postoperative pain
[11-13]. In inflammatory models of rats, TENS was also
shown to significantly reduce pain sensitivity of both
pressure and heat [14,15]. Furthermore, both high- and
low-frequency TENS have been shown to cause hypoal-
gesia through the release of endogenous opioids in the
CNS [16,17]. However, understanding of the mechanism
of TENS analgesia from other way is still rare.
Recent findings from our group reveal that electroa-
cupuncture (EA) treatment relieved inflammatory pain
by inhibiting CFA-mediated activation of ERK1/2 in the
SCDH [18]. It is generally thought that EA and TENS
share the similar therapeutic effect on alleviating pain
hypersensitivity. Therefore, in the current study, usingthe adjuvant-induced inflammation model,we sought to
detemine the contribution of TENS to regulate the acti-
vation of ERK1/2 pathway in the SCDH, thus preventing
early inflammatory pain.
Methods
Animals and CFA injection
Animal care, surgery, and handling procedures were ap-
proved by Zhejiang Chinese Medical University, and car-
ried out in accordance with National Institutions of
Health Guide for the Care and Use of Laboratory Ani-
mals in order to relieve suffering. Adult Male Sprague–
Dawley rats (220 to 250 g) were obtained from the
Department of Animal Sciences, Zhejiang Chinese Med-
ical University. A total of 90 rats were housed under
controlled temperature (23°C ± 1°C), relative humidity
(70% ± 10%), and artificial 12-hour light–dark cycle light-
ing, with distill water and food available ad libitum. Rats
were randomly divided into three groups: (a) the control
group with saline injection (n = 14), with the same man-
ner and volume as CFA injection; (b) the model group
with CFA injection (n = 38); (c) the TENS group with
CFA injection and TENS treatment (n = 38).
After baseline behavioral measurement, inflammatory
pain rat model was induced by injection of 100 μl
Complete Freud’s Adjuvant (CFA, sigma, USA) into the
plantar surface of right hind paw. Rats were then
returned to their cage and allowed to recover. 10 rats
from each group were randomly chosen for behavioral
testing. Furthermore, all rats were anesthetized with 10%
choral hydrate (0.35 ml/100 g, i.p.) and perfused
transcardially with 150 ml cold sterilized saline. Ipsi-
lateral spinal dorsal horns (L4-L6) were removed, pre-
served at −80°C, and used for western immunoblotting
(for p-ERK1/2 and COX-2), qPCR (for COX-2), and
Enzyme-Linked Immunosorbent Assay (ELISA) (for
PGE2).
Behavioral testing
Paw volume were measured with a water plethys-
mometer (Plethysmometer 7140, UGO-Basile, Italy) at
3 d before the experiment (base) and 5 h, 6 h, 25 h after
CFA administration. The paw withdrawal thresholds
(PWTs) were performed as perivously destribed [19]. In
brief, PWTs were tested with an automated von Frey-
type testing device (Dynamic Plantar Aesthesiometer
37450, UGO Basile, Italy). Rats received two training
sessions before the start of the experiment. Rats were
placed on a metal mesh table and adapted to the new
environment (30 min). The mechanical stimulus was de-
livered to the plantar surface of right hind paw below
the floor of the plastic test chamber. A steel rod
(0.5 mm diameter) was pushed against the hind paw
with ascending force (from 0–50 g over a 20 sec period).
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stimulus was automatically stopped and the force at
which the rat withdrew its paw was recorded to the
nearest 0.1 g. The sensitive of mechanical touch to the
paws was measured at 3 d before the experiment (base),
then 5 h, 6 h and 25 h after CFA administration.
TENS treatment
Rats were loosely immobilized by assistants’ hands.
TENS treatment (using two square self-adhesive elec-
trodes [5 × 5 mm]) was administered to the physical de-
nuded skin surround knee and leg of both right and left
hind paws. The first electrode was applied between the
tibia and fibula, 5 mm below the knee, and the other
electrode was placed at the location 3 mm proximal to
the lateral malleolus. When simulated, these sites have
been shown to produce analgesia and reduced allodynia
in a rat model of inflammatory pain [19], and were thus
chosen for our study. Stimulation was delivered by the
output terminals of the HANS Acupuncture Point Nerve
Stimulator (LH-202H, Huawei co., Ltd., Beijing, China).
TENS was delivered with the same parameters constant,
constant square wave current output (pulse width:
0.6 ms at 2 Hz, 0.2 ms at 100 Hz); intensities ranging
from 1–2 mA (each intensity for 15 min, totaling
30 min); at a 2 Hz and 100 Hz alternating frequencies
(automatically shifting between 2 Hz and 100 Hz stimu-
lation for three seconds each). The TENS stimulation
was given at 5 h and 24 h after CFA injection. For elim-
inating the stress effect, rats in model group were also
loosely immobilized by assistants’ hands as same as
TENS group.
Western blot analysis
Tissue sample were homogenized in lysis buffer, contai-
ning a cocktail of phosphatase inhibitors and proteinase
inhibitors. The extracted protein was boiled in sodium
dodecyl sulfate (SDS) sample buffer (100 mm Tris,
ph 6.8, 2% SDS, 20% glycerol, 10%β-mecraptoehanol,
and 0.1% bromophenol blue). Protein sample (20 μg per
lane) separated by SDS-polyacrylamide gel electrophor-
esis and then transferred onto nitrocellulose membranes
(Milliproe, USA). After membrane were blocked(1 h, 37°
C)(tirs-buffered saline [TBS] with 0.2% Tween [TBST]
and 5% skim milk), they were then incubated (overnight,
4°C) with the following primary antibodies: anti-p
-ERK1/2 (1:2000, Cell Signaling Technology, USA), or
anti-COX-2 (1:500, Caymen Chemical company, USA)
in TBST. Membranes were then incubated (1 h at 37°C)
with horseradish peroxidase-conjugated secondary anti-
body (1:10000) and, protein bands were visualized via
ECL (Thermo scientific, USA) (1 min incubation) and
exposed using the ImageQuant Las 4000 (General Elec-
tric company, USA). Band densities were quantified withImage Quant software (General Electric company, USA).
β-actin (1:1000) (Cell Signaling Technology) was used as
internal control.
qPCR
Total RNA was extracted using Trizol Reagent (Invitrogen,
France) containing guanidium thiocyanate, according to
the manufacturer’s instructions. RNA was quantified by
spectrophotometry. First strand cDNA was synthesized
from 1 μg of total RNA (final volume of 10 μl) using the
PrimerScriptW RT reagent Kit with gDNA Eraser (TakaRa,
Japan). Relative mRNA levels were quantified with RT-
PCR using the fluorescent EvaGreen technology. cDNA
was subjected to qPCR using the CFX96™ real-time PCR
detection system (Bio-Rad, USA). Primer premier 5.0 soft-
ware (Premier, Canada) was employed to design oligo-
nucleotide primers specific for rat COX-2 and GAPDH (an
internal control). COX-2: forward: 5′-CACGGACTTG
CTCACTTTGT T-3’, reverse: 5′-AAGCGTTTGCGGTA
CTCATT-3′; GAPDH: forward: 5′-TGCTGAGTATGT
CGTGGAG-3′; reverse: 5′-GTCTTCTGA GTGGCAGT
GAT-3′, with the product sizes 161 bp, and 288 bp, re-
spectively. Reactions (total volume, 20 μl) were incubated
at 95°C for 3 min, followed by 40 cycles of 10 s at 95°C and
30 s at 55.9°C. Water controls were included to ensure spe-
cificity. Each sample was measured in triplicate, and data
points were examined for integrity by analysis of the ampli-
fication plot. Adding the melting curve analysis in the reac-
tion condition, the analytical model: 65°C-95°C, an
increase of 0.5°C every 10 s. The comparative cycle thresh-
old Cq method was used for relative quantification of gene
expression. The amount of COX-2 mRNA normalized to
the GAPDH and relative to a calibrator, was given by
2-ΔΔCq, with Cq indicating the cycle number at which the
fluorescence signal of the PCR product crosses an arbitrary
threshold set within the exponential phase of the PCR, and
ΔΔCq = [(Cqtarget (unknown sample)-Cqend.control (unknown sam-
ple))]-[(Cqtarget (calibrator sample)-Cqend. control (calibrator sample))].
ELISA
PGE2 was measured from extracted protein samples
using a Parameter™ PGE2 Immunoassay ELISA kit
(R&D Systems, USA), according to the manufacturer’s
instructions. Each sample was examined in duplicate
and averaged for data analysis.
Statistical analysis
All data were expressed as means ± standard error mean
(SEM). A repeated measures ANOVA with between-
subjects factors was used to analyze paw volume and PWT
data enabled, and a one-way ANOVA for independent sam-
ples to compare differences between groups at each time
period. The post hoc test for least significant difference
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groups. Significance was reached at values of P < 0.05.Results
Effect of TENS on paw volume in CFA rats
All data of rats’ paw volume in every experimental group at
each time point were shown in Figure 1A. The repeated-
measures ANOVA with between-subjects factors revealed
differences in paw volume over time points (P < 0.01) and
between groups (P < 0.01). There was significant interactive
effect between time points and groups (P < 0.01). Post-hoc
LSD tests indicated there was no remarkable difference in
the severity of paw volume of the whole process between
the TENS group and the model group (P > 0.05).Figure 1 Change of paw volume and paw withdrawal
thresholds at base, 5 h, 6 h, and 25 h after NS/CFA injection in
control group, model group, and TENS group. A) Paw volumes
were measured by a water plethysmometer. B) PWTs were assessed
by using dynamic plantar aesthesiometer. Values represent mean
± SEM; n = 10 for per group. **P < 0.01 versus control group at the
corresponding time point. ▲▲P < 0.01 versus model group at the
corresponding time point.Effect of TENS on inflammatory pain behaviors in CFA
rats
Mean PWTs in all experimental groups at each time point
were shown in Figure 1B. The repeated-measures ANOVA
with between-subjects factors revealed differences over
time points (P < 0.01) and between groups (P < 0.01).
There was significant interactive effect between time
points and groups (P < 0.01). Post-hoc LSD tests indicated
a significant analgesic effect in the TENS group when
compared with the model group (P < 0.01). However,
PWTs in TENS group still showed a significant difference
compared with those in control group (P < 0.01).
At 5 h after CFA injection, the rats began to act overt
behavioral sign, for instant, limping and guarding of the
limb. One-way ANOVA for independent samples identi-
fied significant differences occurred among control, model
and TENS groups from 5 h to 25 h after CFA injection. At
the time points of 5 h, 6 h, and 25 h after CFA injection,
the PWTs of the right hind paw in model and TENS
groups were decreased significantly in comparison with
that in control group (P < 0.01). Following the admi-
nistration of treatment, PWTs in TENS group were sig-
nificant higher than that in model group at 6 h and 25 h
(P < 0.01). However, TENS group still kept a significant
lower PWTs than control group, even at the ending of our
study (P < 0.01).
TENS administration inhibits p-ERK1/2 expression in the
lumbar SCDH
CFA injection produced localized swelling and mechanical
allodynia, which persisted for the duration of the experi-
ment (25 h). The peripheral inflammation induced by the
CFA injection resulted in the induction of p-ERK1/2
in the superficial dorsal horn on the ipsilateral side of
the L4-L6 spinal cord. The expression of p-ERK1/2 sig-
nificantly increased at 5 h and remained higher at 6 h
(P < 0.01), but significantly reduced at 25 h after CFA in-
jection (Figure 2A). The reduction at 25 h promped us to
test if TENS treatment regulated p-ERK1/2 from 5 h to
25 h after CFA injection. The level of p-ERK1/2 in TENS
group at 6 h was decreased (P < 0.01) compared with those
of rats in model group (Figure 2B). However, this effect
was not observed at 25 h (P > 0.05) (Figure 2B).
TENS administration inhibits expression of COX-2 in the
lumbar SCDH
We tested mRNA and protein expressions of COX-2 in
SCDH, to investigate whether TENS regulates COX-2
expression for an analgesic effect. In CFA-treated rats,
mRNA expression of COX-2 was significantly increased
at 5 h and 6 h (P < 0.01) (Figure 3A). However, results
differed at the post-translational level whereby expres-
sion of COX-2 protein was only increased at 6 h after
CFA injection (P < 0.01) (Figure 3B). After once
Figure 2 Expression of p-ERK1/2 in the L4-L6 spinal cord dorsal
horn at control, model and TENS groups after NS/CFA injection.
A) Statistical summary of the densitometric analysis of p-ERK1/2
expressed relative to the value of rats in control group. B) Statistical
summary of the densitometric analysis of p-ERK1/2 expressed in rats
of model group and TENS group at 5 h, 6 h and 25 h after CFA
injection. C) Representative Western bolts show the level of p-ERK1
/2 in rats model group and TENS group at 5 h and 6 h after CFA
injection. Values represent mean ± SEM; n = 4-6 for model and TENS
group at each time point; n = 4-6 for control group. **P < 0.01 versus
control group at each time point. ▲▲P < 0.01 versus model group at
the corresponding time point.
Figure 3 Expression of COX-2 mRNA and protein in the L4-L6
spinal cord dorsal horn at control, model and TENS group after
NS/CFA injection. A) Statistical summary of the COX-2 mRNA
expressed in spinal in rats of control group, model group and TENS
group. B) Statistical summary of the densitometric analysis of COX-2
protein expressed in spinal in rats of control group, model group
and TENS group. C) Representative Western bolts showed the level
of COX-2 in rats of control, model and TENS group at 6 h after CFA
injection. Values represent mean ± SEM; n = 4-6 for model and TENS
group at each time point; n = 4-6 for control group. **P < 0.01 versus
control group at the corresponding time point. ▲▲P < 0.01 versus
model group at the corresponding time point.
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creased both mRNA and protein expressions of COX-2
compared with CFA rats without TENS (P < 0.01)
(Figure 3A, B). However, a significant difference in COX-2
mRNA and protein expressions were observed between
control group and TENS group (P < 0.01) (Figure 3B).
TENS regulating PGE2 level in the lumbar SCDH
PGE2 levels were significantly increased in the CFA group
compared with the control group at only 6 h post modeling(P < 0.01) (Figure 4). Exposure of CFA rats to TENS resulted
in a significant reduction of the PGE2 levels when compared
with those without TENS (P < 0.01). No significant difference
was found between TENS group and control group at 6 h
(P > 0.05).Discussion
The present study demonstrates that application of TENS
at the hind paw attenuates inflammation-induced pain,
Figure 4 Expression of PGE2 protein in the L4-L6 spinal cord
dorsal horn at control, model and TENS group after NS/CFA
injection. Statistical summary of the PGE2 protein expressed in
spinal dorsal horn in rats of control, model and TENS groups. Values
represent mean ± SEM; n = 3-4 for model and TENS group at each
time point; n = 3-4 for control group.**P < 0.01 versus control group
at the corresponding time point. ▲▲P < 0.01 versus model group at
the corresponding time point.
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regulations of COX-2 and PGE2 in SCDH.
Both peripheral inflammatory and central neuropathic
mechanisms are involved in inflammatory pain [20]. ERK1/
2 activated in SCDH neurons was shown to play an import-
ant role in pain hypersensitivity [21]. Zhuang et al. (2005)
demonstrated that sequential activation of ERK1/2 in
SCDH microglia and astrocytes was important for the in-
duction and maintenance of neuropathic pain in rats with
spinal nerve ligation [22]. Mounting evidence exists for the
association of activated ERK1/2 in SCDH neurons and
inflammatory pain [4-9], especially in CFA rat, in which
p-ERK1/2 was shown to peak in 10 min, and remained ele-
vated with a slowly decline for 48 h[5]. Furthermore, intra-
thecal injection of MEK inhibitors has been shown to
inhibit inflammatory mechanical allodynia following hind
paw injection of CFA [5]. In present study, p-ERK1/2 in the
ipsilateral lumbar SCHD increased markedly at 5 h and 6 h
after CFA injection. However, unlike other studies, there is
no significant difference in p-ERK1/2 between the control
and model groups when treated for 25 h. This lack of effect
may have been a result of the activation of ERK1/2 in a
small subset of dorsal horn neurons [5], to which western
blot analysis would have thus been less sensitive in the de-
tection of p-ERK1/2. Taken together, these results suggest
that p-ERK1/2 plays an important role in decreased PWTs
caused by peripheral inflammation, and inhibition of ERK1/
2 activation may be a novel treatment for inflammatory
pain.
Recent studies have reported that expression of spinal
COX-2 mediates mechanical inflammatory pain hypersen-
sitivity [23], which is reduced via the intrathecal injectionof a COX-2 inhibitor [24]. Furthermore, COX-2 expres-
sion has been correlated with ERK1/2 activation, whereby
inhibition of ERK1/2 activation blocked the producton of
COX-2 production [25,26]. Our findings indicated high
expression of COX-2 mRNA in SCDH at 5 h and 6 h after
CFA injection, a finding previously observed [27]. How-
ever, COX-2 protein production at only 6 h indicates the
lag time for its post-translational regulation. Numerous
studies have indicated that ERK1/2 was likely to produce
pain hypersensitivity via the inducing of expression of
pronociceptive substance, such as COX-2 [28]. Therefore,
the results from our study suggest that ERK1/2-COX-2
pathway contributes to the inflammatory pain hypersensi-
tivity in SCDH.
TENS is a non-pharmacologic and noninvasive treatment
for pain, commonly used in patients with acute and chronic
pain. TENS has been shown to be effective for osteoarth-
ritis, rheumatoid arthritis, and postoperative pain [29-31]
and can relieve mechanical allodynia in animal models of
joint, muscle, and cutaneous inflammation [32-34]. TENS
was applied with varying frequencies, from 2 Hz (low) to
100 Hz (high) and different frequencies led to different an-
algesic effects [35]. In the study, the effect of TENS with
alternating frequencies (2Hz/100Hz) on inflammatory pain
induced by CFA injection was evaluated. Our findings that
TENS produces analgesic effect at 6 h after CFA injection
are consistent with previous findings that TENS partially
reversed the hyperalgesia at 4 h after carrageenan-induced
paw inflammation [36]. Despite TENS-meditated analgesia,
we did not detect an anti-inflammatory effect, suggesting
that TENS may inhibit the inflammatory pain hypersensi-
tivity independent of its anti-inflammatory action.
Our previous study has told that EA, at the ST36 acu-
point, inhibited the expression of p-ERK1/2 and p-p38
MAPK in ipsilateral SCDH, and also induced a hyperalgisic
response [18,37]. These results suggested that the modu-
lation of MAPK activation in SCDH as an underlying mec-
hanisms of EA-mediated inhibition of pain. Based on
current literature, the basic mechanisms of TENS- and EA-
mediated analgesia are similar, however, the effects of TENS
on ERK1/2 activation remain unknown, particularly at the
spinal level. In the present study, our findings verified that,
in addition to the modulation of PWTs, TENS treatment
significantly decreased the expression levels of p-ERK1/2
and COX-2 in SCDH at 6 h after CFA injection. Previous
studies at the spinal level have shown that TENS-mediated
reduction of pain hyperalgesia is regulated by the release of
gama-aminobutyric acid (GABA) and decreaed glutamate
levels [38,39], in addition to endogenous opioid signaling
[17]. Furtermore, TENS mediated reduction of hyperalgsia
by reducing the sensitization of dorsal horn neurons th-
rough regulating GABA and glutamate receptors [40]. Glu-
tamate transmission via NMDA receptors was shown to be
essential for ERK1/2 activation in SCDH neurons [41] and
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ronal expression of COX-2 in the spinal cord facilitated the
development of a central component of inflammatory
pain hypersensitivity via increasing neuronal excitation and
reducing inhibition [23,43]. Overall, regulation of the ERK1/
2-COX-2 pathway in SCDH may be the signaling transuda-
tion pathway underlying the TENS-mediated analgesia.
In order to verify the speculation that inhibition of the ac-
tivation of ERK1/2-COX-2 pathway may be the signaling
transudation pathway underlying the TENS-mediated anal-
gesia, protein level of PGE2 in SCDH were detected by
ELISA. Increased PGE2 in the CNS after peripheral inflam-
mation mediated a widespread increase in mechanical pain
sensitivity due to synaptic facilitation within the spinal cord
[43]. Furthermore, the source of PGE2 is predominantly via
COX-2 activation [44]. Our findings reveal that like the
COX-2, the protein level of PGE2 only increased at 6 h after
CFA injection, and TENS significantly decreased the over-
producation of PGE2 in SCDH. The ERK1/2-COX-2 path-
way contributes to inflammatory mechanical allodynia [28],
and COX-2 itself causes pain sensitivity by increasing PGE2
level in SCDH. Therefore, TENS may alleviates pain hyper-
sensitivity by inhibiting ERK1/2-COX-2 pathway activation.
Other MAPK families associated with inflammatory pain
may also play a role [1], and thus the effect of TENS on
other signal transduction may provide additional novel
therapeutic targets. To further elucidate the mechanisms of
TENS-mediated analgesia, future studies could focus on
other MAPK families and inflammation-induced thermal
hyperalgesia.
Conclusions
TENS-mediated analgesia to control peripheral inflamma-
tory pain is independent of anti-inflammatory activity.
Furthermore, CFA-induced activation of the ERK1/2-COX-
2 pathway in SCDH neurons plays an important role in
developing and maintaining inflammatory mechanical
allodynia. Taken together, the analgesic effect of TENS on
inflammatory pain may be associated with the inhibition of
the activaiont of the spinal ERK1/2-COX-2 pathway.
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